Ledger. Australian venture funding, tracked

CEO, Entact Bio

Victoria Richon

Coverage

Stories naming Victoria Richon. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

Series A $81m

Entact Bio Launches with $81 Million Series A to Develop Precision Medicines for Targeted Protein Enhancement

Biotech startup Entact Bio has launched with an $81 million Series A funding its Encompass platform, which designs molecules that enhance protein function, backed by Qiming Venture Partners USA, venBio Partners and others.

Brandon Capital portfolio 6 Dec 2022 Entact BioCitadelDana-Farber Cancer InstituteHarvard Medical SchoolSheppard R&D Consultancy Ltd.University of LiverpoolAbingworthBrandon CapitalWEHIDavid KomanderDavid SheppardJarrod MartoMichael ClagueSara BuhrlageSylvie UrbéUeli NachburVictoria Richon

Something wrong? Tell us